OBJECTIVE: To compare the early and late outcomes of primary percutaneous transluminal coronary angioplasty (PTCA) with fibrinolytic treatment among diabetic patients with acute myocardial infarction (AMI). DESIGN: Retrospective observational study with data obtained from prospective registries. SETTING: Tertiary cardiovascular institution with 24 hour acute interventional facilities. PATIENTS: 202 consecutive diabetic patients with AMI receiving reperfusion treatment within six hours of symptom onset. INTERVENTIONS: Fibrinolytic treatment was administered to 99 patients, and 103 patients underwent primary PTCA. Most patients undergoing PTCA received adjunctive stenting (94.2%) and glycoprotein IIb/IIIa inhibition (63.1%). MAIN OUTCOME MEASURES: Death, non-fatal reinfarction, and target vessel revascularisation at 30 days and one year were assessed. RESULTS: Baseline characteristics were similar in these two treatment groups except that the proportion of patients with Killip class III or IV was considerably higher in those treated with PTCA (15.5% v 6.1%, p = 0.03) and time to treatment was significantly longer (103.7 v 68.0 minutes, p < 0.001). Among those treated with PTCA, the rates for in-hospital recurrent ischaemia (5.8% v 17.2%, p = 0.011) and target vessel revascularisation at one year (19.4% v 36.4%, p = 0.007) were lower. Death or reinfarction at one year was also reduced among those treated with PTCA (17.5% v 31.3%, p = 0.02), with an adjusted relative risk of 0.29 (95% confidence interval 0.15 to 0.57) compared with fibrinolysis. CONCLUSION: Among diabetic patients with AMI, primary PTCA was associated with reduced early and late adverse events compared with fibrinolytic treatment.
OBJECTIVE: To compare the early and late outcomes of primary percutaneous transluminal coronary angioplasty (PTCA) with fibrinolytic treatment among diabeticpatients with acute myocardial infarction (AMI). DESIGN: Retrospective observational study with data obtained from prospective registries. SETTING: Tertiary cardiovascular institution with 24 hour acute interventional facilities. PATIENTS: 202 consecutive diabeticpatients with AMI receiving reperfusion treatment within six hours of symptom onset. INTERVENTIONS: Fibrinolytic treatment was administered to 99 patients, and 103 patients underwent primary PTCA. Most patients undergoing PTCA received adjunctive stenting (94.2%) and glycoprotein IIb/IIIa inhibition (63.1%). MAIN OUTCOME MEASURES: Death, non-fatal reinfarction, and target vessel revascularisation at 30 days and one year were assessed. RESULTS: Baseline characteristics were similar in these two treatment groups except that the proportion of patients with Killip class III or IV was considerably higher in those treated with PTCA (15.5% v 6.1%, p = 0.03) and time to treatment was significantly longer (103.7 v 68.0 minutes, p < 0.001). Among those treated with PTCA, the rates for in-hospital recurrent ischaemia (5.8% v 17.2%, p = 0.011) and target vessel revascularisation at one year (19.4% v 36.4%, p = 0.007) were lower. Death or reinfarction at one year was also reduced among those treated with PTCA (17.5% v 31.3%, p = 0.02), with an adjusted relative risk of 0.29 (95% confidence interval 0.15 to 0.57) compared with fibrinolysis. CONCLUSION: Among diabeticpatients with AMI, primary PTCA was associated with reduced early and late adverse events compared with fibrinolytic treatment.
Authors: K H Mak; D J Moliterno; C B Granger; D P Miller; H D White; R G Wilcox; R M Califf; E J Topol Journal: J Am Coll Cardiol Date: 1997-07 Impact factor: 24.094
Authors: L Agati; P Voci; P Hickle; D C Vizza; C Autore; F Fedele; S B Feinstein; A Dagianti Journal: J Am Coll Cardiol Date: 1998-02 Impact factor: 24.094
Authors: S L Woodfield; C F Lundergan; J S Reiner; S W Greenhouse; M A Thompson; S C Rohrbeck; Y Deychak; M L Simoons; R M Califf; E J Topol; A M Ross Journal: J Am Coll Cardiol Date: 1996-12 Impact factor: 24.094
Authors: W D Weaver; R J Simes; A Betriu; C L Grines; F Zijlstra; E Garcia; L Grinfeld; R J Gibbons; E E Ribeiro; M A DeWood; F Ribichini Journal: JAMA Date: 1997-12-17 Impact factor: 56.272
Authors: G W Stone; B R Brodie; J J Griffin; M C Morice; C Costantini; F G St Goar; P A Overlie; J J Popma; J McDonnell; D Jones; W W O'Neill; C L Grines Journal: J Am Coll Cardiol Date: 1998-01 Impact factor: 24.094
Authors: A R Fernandez; R F Sequeira; S Chakko; L F Correa; E J de Marchena; R A Chahine; D A Franceour; R J Myerburg Journal: J Am Coll Cardiol Date: 1995-09 Impact factor: 24.094
Authors: R M Califf; H D White; F Van de Werf; Z Sadowski; P W Armstrong; A Vahanian; M L Simoons; R J Simes; K L Lee; E J Topol Journal: Circulation Date: 1996-09-15 Impact factor: 29.690
Authors: K L Lee; L H Woodlief; E J Topol; W D Weaver; A Betriu; J Col; M Simoons; P Aylward; F Van de Werf; R M Califf Journal: Circulation Date: 1995-03-15 Impact factor: 29.690
Authors: R J van der Schaaf; J P S Henriques; J J Wiersma; K T Koch; J Baan; K J J Mulder; J D Durrer; J G P Tijssen; J J Piek; R J de Winter Journal: Heart Date: 2005-05-12 Impact factor: 5.994
Authors: J R Timmer; I C C van der Horst; J P S Henriques; K Thomas; H J G Bilo; J C A Hoorntje; M J de Boer; H Suryapranata; F Zijlstra Journal: Neth Heart J Date: 2003-10 Impact factor: 2.380
Authors: Eva C Knudsen; Ingebjørg Seljeflot; Michael Abdelnoor; Jan Eritsland; Arild Mangschau; Carl Müller; Harald Arnesen; Geir O Andersen Journal: BMC Endocr Disord Date: 2011-07-29 Impact factor: 2.763
Authors: Min Goo Lee; Myung Ho Jeong; Youngkeun Ahn; Shung Chull Chae; Seung Ho Hur; Taek Jong Hong; Young Jo Kim; In Whan Seong; Jei Keon Chae; Jay Young Rhew; In Ho Chae; Myeong Chan Cho; Jang Ho Bae; Seung Woon Rha; Chong Jim Kim; Donghoon Choi; Yang Soo Jang; Junghan Yoon; Wook Sung Chung; Jeong Gwan Cho; Ki Bae Seung; Seung Jung Park Journal: Korean Circ J Date: 2009-06-30 Impact factor: 3.243